$SYBX

Synlogic Inc

  • NASDAQ
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Pharmaceutical Preparation Manufacturing

PRICE

$0.5 ▲2.775%

Extented Hours

VOLUME

426,588

DAY RANGE

0.485 - 0.5819

52 WEEK

0.453 - 1.35

Join Discuss about SYBX with like-minded investors

profile
@dros #droscrew
recently

Upgrades 11/24: $AEG $CVX $DEO $DLTR $FMX $GRUB $SYBX $YSG .. Downgrades 11/24: $BABA $BBY $GPS $HTA $JACK $JWN $NOAH $PLAN $RPM $TITN +Initiations 11/24: $AURA $AVY $BFRI $BTTX $CFG $DSEY $GPK $LIAN $MYNA $OCUP $PLRX $SLGN $SPAQ $SPOT $TRDA .. -Initiations 11/24:

92 Replies 12 👍 10 🔥

profile
@nepestheone #StockTraders.NET
recently

MIC WATCHLIST SDC - Looking for a morning pop to scale in short 7.50 / 8.00 VSTM - Ideally 3.50 / 3.70 / 4.00 to scale in 30% max size until confirmation. STOP over 4.15 SYBX - Watching for a volume rush at open due to ETB. Will let this trade out.. Waiting for a death candle then will attack HLBZ - Would love a r/g rejection to short this. Mostly reactive as SSR will turn on at open CRVS - Wouldn't be surprised to see this go red and immediately reclaim and trap. For me will look for a 6.00 / 6.50 rejection to get involved ZEVO - SSR is on. Maybe a 6.50 / 7.00 / 7.50 push to scale in. stop is over pre mkt HOD. 30% max size until confirm EDSA - ETB. Potential runner of the day. Ignoring it for now APRE - 6.00 / 6.50 line

53 Replies 8 👍 10 🔥

profile
@Navneet #droscrew
recently

$sybx popped

132 Replies 12 👍 14 🔥

Key Metrics

Market Cap

38.88 M

Beta

0.81

Avg. Volume

728.80 K

Shares Outstanding

68.21 M

Yield

0%

Public Float

0

Next Earnings Date

2023-08-10

Next Dividend Date

Company Information

at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre

CEO: Aoife Brennan

Website:

HQ: 301 Binney St Ste 402 Cambridge, 02142-1030 Massachusetts

Related News